Cargando…
Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model
Gene replacement for Duchenne muscular dystrophy (DMD) with micro-dystrophins has entered clinical trials, but efficacy in preventing heart failure is unknown. Although most patients with DMD die from heart failure, cardiomyopathy is undetectable until the teens, so efficacy from trials in young boy...
Autores principales: | Howard, Zachary M., Dorn, Lisa E., Lowe, Jeovanna, Gertzen, Megan D., Ciccone, Pierce, Rastogi, Neha, Odom, Guy L., Accornero, Federica, Chamberlain, Jeffrey S., Rafael-Fortney, Jill A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119181/ https://www.ncbi.nlm.nih.gov/pubmed/33651713 http://dx.doi.org/10.1172/jci.insight.146511 |
Ejemplares similares
-
Micro-dystrophin gene therapy demonstrates long-term cardiac efficacy in a severe Duchenne muscular dystrophy model
por: Piepho, Arden B., et al.
Publicado: (2023) -
Metabolic Dysfunction and Altered Mitochondrial Dynamics in the Utrophin-Dystrophin Deficient Mouse Model of Duchenne Muscular Dystrophy
por: Pant, Meghna, et al.
Publicado: (2015) -
Muscle Twitch Kinetics Are Dependent on Muscle Group, Disease State, and Age in Duchenne Muscular Dystrophy Mouse Models
por: Peczkowski, Kyra K., et al.
Publicado: (2020) -
Corrigendum: Muscle Twitch Kinetics Are Dependent on Muscle Group, Disease State, and Age in Duchenne Muscular Dystrophy Mouse Models
por: Peczkowski, Kyra K., et al.
Publicado: (2022) -
Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy
por: Howard, Zachary M., et al.
Publicado: (2022)